Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vecabrutinib (SNS-062) is a potent and noncovalent BTK and ITK inhibitor (Kd: 0.3 nM and 2.2 nM, respectively). Vecabrutinib displays an IC50 of 24 nM for ITK.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 30,500 | |||
5 mg | 在庫あり | ¥ 75,500 | |||
10 mg | 在庫あり | ¥ 123,500 | |||
25 mg | 在庫あり | ¥ 200,500 | |||
50 mg | 在庫あり | ¥ 271,000 | |||
100 mg | 在庫あり | ¥ 372,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 88,500 |
説明 | Vecabrutinib (SNS-062) is a potent and noncovalent BTK and ITK inhibitor (Kd: 0.3 nM and 2.2 nM, respectively). Vecabrutinib displays an IC50 of 24 nM for ITK. |
ターゲット&IC50 | BTK:(kd)0.3 nM, ITK:2.2 nM(kd), ITK:24 nM |
In vitro | Vecabrutinib is six times more potent than PCI-32765 and greater than 640 times more potent than acalabrutinib against C481S BTK. Vecabrutinib inhibits pBTK in human whole blood (average IC50: 50 nM). Vecabrutinib inhibits WT and C481S BTK with similar IC50s (pBTK IC50s: 2.9 nM and 4.4 nM for WT BTK and C481S BTK). In a recombinant kinase assay, IC50s of Vecabrutinib against WT BTK and C481S BTK are 4.6 nM and 1.1 nM. Vecabrutinib retains activity against the mutated BTK variant. Vecabrutinib demonstrates dose-dependent inhibition of BTK in primary patient CLL cells comparable to PCI-32765 via immunoblot for BTK phosphorylation. Vecabrutinib decreases the viability of primary CLL cells in the presence of HS5 stromal protection by 5.5% [1][2]. |
In vivo | Vecabrutinib is well tolerated with continuous drug levels. Vecabrutinib has good oral bioavailability in rat and dog (%F ≥ 40%) and a terminal half-life of 5 to 6 hours [1]. |
別名 | SNS-062 |
分子量 | 529.92 |
分子式 | C22H24ClF4N7O2 |
CAS No. | 1510829-06-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 112.5 mg/mL (212.3 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Vecabrutinib 1510829-06-7 Angiogenesis Tyrosine Kinase/Adaptors BTK Tyrosine Kinases SNS 062 SNS-062 SNS062 Inhibitor inhibitor inhibit